Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death.
Acquired Immunodeficiency Syndrome
Endogenous sodium potassium ATPase inhibition related biochemical cascade and the acquired immunodeficiency syndrome--neural regulation of viral replication and immune response to the virus.
Acquired Immunodeficiency Syndrome
Hypothalamic digoxin, hemispheric dominance and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Acute Coronary Syndrome
Defining the role of high-dose statins in PCI.
Acute Coronary Syndrome
Early statin initiation and outcomes in patients with acute coronary syndromes.
Acute Coronary Syndrome
Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction.
Acute Coronary Syndrome
Early use of statins in acute coronary syndromes.
Acute Coronary Syndrome
Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction.
Acute Coronary Syndrome
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
Acute Coronary Syndrome
How aggressive should lipid lowering be among patients with acute coronary syndromes?
Acute Coronary Syndrome
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Acute Coronary Syndrome
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
Acute Coronary Syndrome
Lipids and stroke: the opportunity of lipid-lowering treatment.
Acute Coronary Syndrome
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Acute Coronary Syndrome
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Acute Coronary Syndrome
Statin withdrawal: clinical implications and molecular mechanisms.
Acute Coronary Syndrome
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Acute Coronary Syndrome
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Acute Coronary Syndrome
Utility of early high dose statins in acute coronary syndrome.
Acute Coronary Syndrome
[Oxidized low-density lipoprotein enhances the expressions of SREBP-2 and HMGCR mRNA in macrophages derived from the monocytes of patients with acute coronary syndrome]
Acute Coronary Syndrome
[Statins in the management of acute coronary syndrome]
Acute Kidney Injury
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Acute Kidney Injury
HMG-CoA Reductase Activation and Urinary Pellet Cholesterol Elevations in Acute Kidney Injury.
Acute Kidney Injury
Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine.
Acute Kidney Injury
Renal ischemia-induced cholesterol loading: transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene.
Acute Kidney Injury
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Acute Kidney Injury
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
Acute Kidney Injury
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Acute Lung Injury
Long-term Simvastatin Administration Attenuates Lung Injury and Oxidative Stress in Murine Acute Lung Injury Models Induced by Oleic Acid and Endotoxin.
Acute Lung Injury
Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury.
Adenocarcinoma
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
Adenocarcinoma
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Adenocarcinoma
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Adenocarcinoma
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Adenocarcinoma
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Adenocarcinoma
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Adenocarcinoma of Lung
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
Adenocarcinoma of Lung
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Adenocarcinoma, Bronchiolo-Alveolar
Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
Adenoma
Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Albuminuria
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Albuminuria
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Albuminuria
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Albuminuria
Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury.
Alveolitis, Extrinsic Allergic
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
Alzheimer Disease
A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.
Alzheimer Disease
Association between statin use and Alzheimer's disease.
Alzheimer Disease
Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
Alzheimer Disease
Atorvastatin ameliorates cognitive impairment, A?1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
Alzheimer Disease
Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.
Alzheimer Disease
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Alzheimer Disease
Can statins put the brakes on Alzheimer's disease?
Alzheimer Disease
Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Alzheimer Disease
Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Alzheimer Disease
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Alzheimer Disease
Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.
Alzheimer Disease
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
Alzheimer Disease
Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk.
Alzheimer Disease
High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.
Alzheimer Disease
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
Alzheimer Disease
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
Alzheimer Disease
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
Alzheimer Disease
Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk.
Alzheimer Disease
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Alzheimer Disease
Mechanisms of statin-mediated inhibition of small G-protein function.
Alzheimer Disease
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Alzheimer Disease
Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
Alzheimer Disease
Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
Alzheimer Disease
Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimer's Disease.
Alzheimer Disease
Simvastatin inhibits protein isoprenylation in the brain.
Alzheimer Disease
Statins and neuroprotection: a prescription to move the field forward.
Alzheimer Disease
Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.
Alzheimer Disease
Therapeutic approaches to the treatment of Alzheimer's disease.
Alzheimer Disease
[Direct neuronal effects of statins]
Amebiasis
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Amyotrophic Lateral Sclerosis
Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.
Anaphylaxis
Exercise-Induced Anaphylaxis in an Air Force Aviator Taking a HMG-CoA Reductase Inhibitor: A Case Report and Review of the Presentation, Diagnoses, and Treatment.
Anemia, Hypochromic
Overexpression of farnesyl diphosphate synthase in Arabidopsis mitochondria triggers light-dependent lesion formation and alters cytokinin homeostasis.
Aneurysm
A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Aneurysm
Medical management of small abdominal aortic aneurysms.
Angina Pectoris
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Angina, Stable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Angina, Stable
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Angina, Unstable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Angina, Unstable
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Angina, Unstable
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
Angina, Unstable
[Statins decreases expression of five inflammation-associated microRNAs in the plasma of patients with unstable angina].
Aortic Aneurysm, Abdominal
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
Aortic Aneurysm, Abdominal
A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms.
Aortic Aneurysm, Abdominal
HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms.
Aortic Valve Stenosis
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Aortic Valve Stenosis
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Arterial Occlusive Diseases
Peripheral arterial disease: a review of disease awareness and management.
Arteriosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Arteriosclerosis
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Arteriosclerosis
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Arteriosclerosis
HMG-CoA reductase inhibitors in organ transplantation.
Arteritis
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
Arthritis
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Arthritis, Experimental
Effects of pravastatin in murine collagen-induced arthritis.
Arthritis, Rheumatoid
Bone protective effect of simvastatin in experimental arthritis.
Arthritis, Rheumatoid
Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.
Arthritis, Rheumatoid
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
Aspergillosis, Allergic Bronchopulmonary
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Asthma
Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Asthma
Innovations in asthma therapy: is there a role for inhaled statins?
Asthma
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Statin Exposure is Associated with Decreased Asthma-Related Emergency Department Visits and Oral Corticosteroid Use.
Asthma
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Asthma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Asthma
[Simvastatin induces eosinophil apoptosis in vitro]
Atherosclerosis
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Atherosclerosis
A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.
Atherosclerosis
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Atherosclerosis
A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits.
Atherosclerosis
A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Atherosclerosis
Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells.
Atherosclerosis
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Atherosclerosis
An in vitro method using vascular smooth muscle cells to study the effect of compounds on cell proliferation and intracellular lipid accumulation.
Atherosclerosis
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Atherosclerosis
Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.
Atherosclerosis
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Atherosclerosis
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atherosclerosis
Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.
Atherosclerosis
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Atherosclerosis
Biological knowledge-driven analysis of epistasis in human GWAS with application to lipid traits.
Atherosclerosis
CE: Triglycerides: Do They Matter?
Atherosclerosis
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Atherosclerosis
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Atherosclerosis
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Atherosclerosis
Comparative tolerability of the HMG-CoA reductase inhibitors.
Atherosclerosis
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Atherosclerosis
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Atherosclerosis
Coronary Plaque Burden at Coronary CT Angiography in Asymptomatic Men and Women.
Atherosclerosis
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Atherosclerosis
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Atherosclerosis
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Atherosclerosis
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Atherosclerosis
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Atherosclerosis
Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system.
Atherosclerosis
Drug Insight: using statins to treat neuroinflammatory disease.
Atherosclerosis
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Atherosclerosis
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Atherosclerosis
Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Atherosclerosis
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Atherosclerosis
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Atherosclerosis
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Atherosclerosis
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Atherosclerosis
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Atherosclerosis
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Atherosclerosis
Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
Atherosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Atherosclerosis
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Atherosclerosis
Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals.
Atherosclerosis
Effects of statins on adhesion molecule expression in endothelial cells.
Atherosclerosis
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Atherosclerosis
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Atherosclerosis
Genomic analysis of circulating cells: a window into atherosclerosis.
Atherosclerosis
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
Atherosclerosis
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Atherosclerosis
HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis.
Atherosclerosis
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Atherosclerosis
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Atherosclerosis
HMG-CoA reductase inhibitors: a look back and a look ahead.
Atherosclerosis
HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol.
Atherosclerosis
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Atherosclerosis
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
Atherosclerosis
Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.
Atherosclerosis
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Atherosclerosis
In vitro screening for ?-hydroxy-?-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
Atherosclerosis
Influence of statins on MHC class I expression.
Atherosclerosis
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Atherosclerosis
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Atherosclerosis
Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations.
Atherosclerosis
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix.
Atherosclerosis
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Atherosclerosis
Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Atherosclerosis
Lycopene regulation of cholesterol synthesis and efflux in human macrophages.
Atherosclerosis
Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
Atherosclerosis
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Atherosclerosis
Molecular mechanisms underlying the onset of degenerative aortic valve disease.
Atherosclerosis
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Atherosclerosis
Optimizing cardiovascular outcomes in diabetes mellitus.
Atherosclerosis
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Atherosclerosis
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Atherosclerosis
Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.
Atherosclerosis
Pleiotropic effects of HMG-CoA reductase inhibitors.
Atherosclerosis
Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.
Atherosclerosis
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Atherosclerosis
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Atherosclerosis
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Atherosclerosis
Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors.
Atherosclerosis
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Atherosclerosis
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Atherosclerosis
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Atherosclerosis
Rosuvastatin Improves Endothelial Function of db/db Mice: Role of Angiotensin II Type 1 Receptors and Oxidative Stress.
Atherosclerosis
Rosuvastatin: a review of its effect on atherosclerosis.
Atherosclerosis
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Atherosclerosis
Simvastatin Increases ADAMTS13 Expression in Podocytes.
Atherosclerosis
Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPAR?-CD36 pathway.
Atherosclerosis
Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA.
Atherosclerosis
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Atherosclerosis
Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.
Atherosclerosis
Statin treatment and progression of atherosclerotic plaque burden.
Atherosclerosis
Statin-stimulated nitric oxide release from endothelium.
Atherosclerosis
Statins and demyelination.
Atherosclerosis
Statins in the treatment of central nervous system autoimmune disease.
Atherosclerosis
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Atherosclerosis
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.
Atherosclerosis
Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS).
Atherosclerosis
The effect of statins on postprandial lipemia.
Atherosclerosis
The effects of HMG-CoA reductase inhibitor on vascular progenitor cells.
Atherosclerosis
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Atherosclerosis
The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.
Atherosclerosis
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Atherosclerosis
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
Atherosclerosis
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
Atherosclerosis
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
Atherosclerosis
The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
Atherosclerosis
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Atherosclerosis
Torcetrapib + atorvastatin (Pfizer).
Atherosclerosis
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Atherosclerosis
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Atherosclerosis
Use of Statins for Secondary Prevention.
Atherosclerosis
Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
Atherosclerosis
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Atherosclerosis
[Anti-atherosclerotic actions of HMG-CoA reductase inhibitors]
Atherosclerosis
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]
Atherosclerosis
[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience]
Atherosclerosis
[Pleiotropic effects of statins]
Atherosclerosis
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
Atrial Fibrillation
Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?
Atrial Fibrillation
Fluvastatin Reduces Pulmonary Vein Spontaneous Activity Through Nitric Oxide Pathway.
Atrial Fibrillation
Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
Atrial Fibrillation
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
Atrial Fibrillation
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery.
Atrial Fibrillation
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Atrial Fibrillation
Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during post-myocardial infarction remodeling process.
Atrial Fibrillation
Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Atrial Fibrillation
Targeting inflammation and oxidative stress in atrial fibrillation: Role of HMG-CoA reductase inhibition with statins.
Atrial Fibrillation
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
Atrial Fibrillation
The role of statins in cancer therapy.
Autoimmune Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Autoimmune Diseases
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
Autoimmune Diseases
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Autoimmune Diseases
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Autoimmune Diseases
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Autoimmune Diseases
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Bacteremia
The role of statin therapy in sepsis.
Bacterial Infections
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Blister
3-hydroxy-3-methyl glutaryl coenzyme A reductase: an essential actor in the biosynthesis of cantharidin in the blister beetle Epicauta chinensis Laporte.
Bone Resorption
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Bone Resorption
Bone protective effect of simvastatin in experimental arthritis.
Bone Resorption
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Brain Injuries
HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons.
Brain Injuries
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Brain Injuries
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: A translational approach.
Brain Injuries
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Injuries, Traumatic
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Brain Injuries, Traumatic
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Brain Injuries, Traumatic
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Brain Injuries, Traumatic
Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
Brain Injuries, Traumatic
Statins and neuroprotection: a prescription to move the field forward.
Brain Ischemia
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Brain Ischemia
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Brain Ischemia
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Brain Ischemia
Alterations of interneurons of the gerbil hippocampus after transient cerebral ischemia: effect of pitavastatin.
Brain Ischemia
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
Brain Ischemia
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Brain Ischemia
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Brain Ischemia
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Ischemia
[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]
Brain Neoplasms
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
Breast Neoplasms
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
Breast Neoplasms
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
Breast Neoplasms
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Breast Neoplasms
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Breast Neoplasms
Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.
Breast Neoplasms
Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.
Breast Neoplasms
Dysregulation of the mevalonate pathway promotes transformation.
Breast Neoplasms
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Breast Neoplasms
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
Breast Neoplasms
Factors released from human breast-cancer cells counteract the inhibitory effects of mevinolin on DNA-synthesis and morphology but not on hmg coa reductase-activity.
Breast Neoplasms
Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Breast Neoplasms
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Breast Neoplasms
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Breast Neoplasms
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Breast Neoplasms
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Breast Neoplasms
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
Breast Neoplasms
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Breast Neoplasms
Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.
Breast Neoplasms
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
Breast Neoplasms
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Breast Neoplasms
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
Breast Neoplasms
Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells.
Breast Neoplasms
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Breast Neoplasms
Statins and cancer development.
Breast Neoplasms
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Breast Neoplasms
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Breast Neoplasms
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Breast Neoplasms
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Breast Neoplasms
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Breast Neoplasms
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Breast Neoplasms, Male
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Bronchitis, Chronic
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Carcinogenesis
A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis.
Carcinogenesis
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Carcinogenesis
Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Carcinogenesis
Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice.
Carcinogenesis
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Carcinogenesis
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Carcinogenesis
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Carcinogenesis
Hypolipidemic effect of ginger in 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis.
Carcinogenesis
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Carcinogenesis
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Carcinogenesis
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Carcinogenesis
Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids.
Carcinogenesis
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Carcinogenesis
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases.
Carcinoma
3-Hydroxy-3-methylglutaryl coenzyme a reductase activity in liver of athymic mice with or without an implanted human carcinoma.
Carcinoma
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Carcinoma
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Carcinoma
Characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human adrenal cortex.
Carcinoma
Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells.
Carcinoma
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Carcinoma
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Carcinoma
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
Carcinoma
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Carcinoma
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Carcinoma
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Carcinoma
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Carcinoma
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Carcinoma
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Carcinoma
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Carcinoma
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Carcinoma
Synergistic Impact of d-?-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells.
Carcinoma, Acinar Cell
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma, Hepatocellular
A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG-CoA reductase in human total RNA. Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor.
Carcinoma, Hepatocellular
Activation of AMP-kinase by Policosanol Requires Peroxisomal Metabolism.
Carcinoma, Hepatocellular
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
Carcinoma, Hepatocellular
An improved assay of 3-hydroxy-3-methylglutaryl-CoA reductase activity in Reuber H35 hepatoma cells without microsomes isolation.
Carcinoma, Hepatocellular
Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase.
Carcinoma, Hepatocellular
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
Carcinoma, Hepatocellular
Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.
Carcinoma, Hepatocellular
Cholesterol-lowering effect of Aralia elata (Miq.) Seem via the activation of SREBP-2 and the LDL receptor.
Carcinoma, Hepatocellular
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Carcinoma, Hepatocellular
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Carcinoma, Hepatocellular
Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels.
Carcinoma, Hepatocellular
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
Carcinoma, Hepatocellular
Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells.
Carcinoma, Hepatocellular
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Carcinoma, Hepatocellular
Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.
Carcinoma, Hepatocellular
Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway.
Carcinoma, Hepatocellular
Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Carcinoma, Hepatocellular
Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells.
Carcinoma, Hepatocellular
Growth-rate-related and hydroxysterol-induced changes in membrane fluidity of cultured hepatoma cells: correlation with 3-hydroxy-3-methyl glutaryl CoA reductase activity.
Carcinoma, Hepatocellular
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
Carcinoma, Hepatocellular
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis.
Carcinoma, Hepatocellular
Identification of insulin-responsive regions in the HMG-CoA reductase promoter.
Carcinoma, Hepatocellular
Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis.
Carcinoma, Hepatocellular
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms.20l.
Carcinoma, Hepatocellular
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Carcinoma, Hepatocellular
Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels.
Carcinoma, Hepatocellular
Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
Carcinoma, Hepatocellular
Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
Carcinoma, Hepatocellular
MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1.
Carcinoma, Hepatocellular
Modification of phospholipids fatty acid composition in reuber H35 hepatoma cells: effect on HMG-CoA reductase activity.
Carcinoma, Hepatocellular
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
Carcinoma, Hepatocellular
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells.
Carcinoma, Hepatocellular
Partial "feedback control" of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in primary hepatocellular carcinomas.
Carcinoma, Hepatocellular
Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice.
Carcinoma, Hepatocellular
Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures.
Carcinoma, Hepatocellular
Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
Carcinoma, Hepatocellular
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Carcinoma, Hepatocellular
Properties of 3-hydroxy-3-methylglutaryl coenzyme A reductase solubilized from rat liver and hepatoma.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma tissue culture cells by serum lipoproteins.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in minimal deviation hepatoma 7288C. Immunological measurements in hepatoma tissue culture cells.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
Carcinoma, Hepatocellular
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A and 5123t.c.
Carcinoma, Hepatocellular
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Carcinoma, Hepatocellular
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Carcinoma, Hepatocellular
Regulation of the Lactobacillus Strains on HMGCoA Reductase Gene Transcription in Human HepG2 Cells via Nuclear Factor-?B.
Carcinoma, Hepatocellular
Regulation of the rate of sterol synthesis and the level of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas.
Carcinoma, Hepatocellular
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Carcinoma, Hepatocellular
Reversible phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase in Morris hepatomas.
Carcinoma, Hepatocellular
RHOA is a modulator of the cholesterol-lowering effects of statin.
Carcinoma, Hepatocellular
Robinetinidol-flavone attenuates cholesterol synthesis in hepatoma cells via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Carcinoma, Hepatocellular
Role of mevalonate in regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured cells and their cytoplasts.
Carcinoma, Hepatocellular
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Carcinoma, Hepatocellular
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Carcinoma, Hepatocellular
Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism.
Carcinoma, Hepatocellular
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.
Carcinoma, Hepatocellular
SUGP1 is a novel regulator of cholesterol metabolism.
Carcinoma, Hepatocellular
Supernatant protein factor requires phosphorylation and interaction with Golgi to stimulate cholesterol synthesis in hepatoma cells.
Carcinoma, Hepatocellular
Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Carcinoma, Hepatocellular
The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2.
Carcinoma, Hepatocellular
The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2.
Carcinoma, Hepatocellular
The regulation of beta-hydroxy-beta-methylglutaryl coenzyme A reductase in Morris hepatomas 5123C, 7800, and 9618A.
Carcinoma, Hepatocellular
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
Carcinoma, Hepatocellular
[Affinity of 3-beta-(2-hydroxyethoxy)-5-alpha-cholest-8(14)-ene-15-one to oxysterol binding protein and its metabolism in HepG2 hepatoma cells]
Carcinoma, Hepatocellular
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
Carcinoma, Intraductal, Noninfiltrating
The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Carcinoma, Mucoepidermoid
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Carcinoma, Ovarian Epithelial
Impact of statin therapy on survival in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Carcinoma, Renal Cell
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Carcinoma, Renal Cell
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Carcinoma, Renal Cell
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Cardiomegaly
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Cardiomegaly
HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Cardiomegaly
Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy.
Cardiomegaly
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Cardiomegaly
Matrix Metalloproteinase-2 Mediates a Mechanism of Metabolic Cardioprotection Consisting of Negative Regulation of the Sterol Regulatory Element-Binding Protein-2/3-Hydroxy-3-Methylglutaryl-CoA Reductase Pathway in the Heart.
Cardiomegaly
Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy.
Cardiomegaly
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Cardiomegaly
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Cardiomegaly
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
Cardiomegaly
Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway.
Cardiomegaly
Statin therapy for cardiac hypertrophy and heart failure.
Cardiomegaly
Statins and the myocardium.
Cardiomegaly
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
Cardiomegaly
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Cardiomyopathies
Inflammation in chronic heart failure.
Cardiomyopathies
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Cardiomyopathy, Hypertrophic
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Cardiotoxicity
Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors.
Cardiovascular Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
Cardiovascular Diseases
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
Cardiovascular Diseases
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Cardiovascular Diseases
A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
Cardiovascular Diseases
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.
Cardiovascular Diseases
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Cardiovascular Diseases
An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.
Cardiovascular Diseases
Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-?B and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages.
Cardiovascular Diseases
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.
Cardiovascular Diseases
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
Cardiovascular Diseases
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?: A Retrospective Cohort Study.
Cardiovascular Diseases
Association Between Statin Use and Prevalence of Exercise-Related Injuries: A Cross-Sectional Survey of Amateur Runners in the Netherlands.
Cardiovascular Diseases
Association of race with cumulative exposure to statins in dialysis.
Cardiovascular Diseases
Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression.
Cardiovascular Diseases
Bone protective effect of simvastatin in experimental arthritis.
Cardiovascular Diseases
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Cardiovascular Diseases
Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Cardiovascular Diseases
Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.
Cardiovascular Diseases
CE: Triglycerides: Do They Matter?
Cardiovascular Diseases
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Cardiovascular Diseases
Clinical implications of pharmacogenetic variation on the effects of statins.
Cardiovascular Diseases
Combination Therapy of Amlodipine and Atorvastatin Has More Beneficial Vascular Effects Than Monotherapy in Salt-Sensitive Hypertension.
Cardiovascular Diseases
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Cardiovascular Diseases
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Cardiovascular Diseases
Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).
Cardiovascular Diseases
Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Cardiovascular Diseases
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Cardiovascular Diseases
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Cardiovascular Diseases
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Cardiovascular Diseases
Direct vascular effects of HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Dyslipidemia in older adults.
Cardiovascular Diseases
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Cardiovascular Diseases
Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Cardiovascular Diseases
Effect of monthly atorvastatin treatment on hemostasis.
Cardiovascular Diseases
Effect of statins on breast cancer recurrence and mortality: a review.
Cardiovascular Diseases
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Cardiovascular Diseases
Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Cardiovascular Diseases
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Cardiovascular Diseases
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Cardiovascular Diseases
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Cardiovascular Diseases
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Cardiovascular Diseases
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Cardiovascular Diseases
Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
Cardiovascular Diseases
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Cardiovascular Diseases
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Cardiovascular Diseases
Identification of novel inhibitors of dietary lipid absorption using zebrafish.
Cardiovascular Diseases
Implications of recent statin trials for primary care practice.
Cardiovascular Diseases
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Cardiovascular Diseases
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
Cardiovascular Diseases
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Cardiovascular Diseases
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Cardiovascular Diseases
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Cardiovascular Diseases
Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Lipid lowering in liver and chronic kidney disease.
Cardiovascular Diseases
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.
Cardiovascular Diseases
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
Cardiovascular Diseases
Molecular mechanisms underlying the effects of statins in the central nervous system.
Cardiovascular Diseases
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.
Cardiovascular Diseases
Neuroprotective Effect of Simvastatin via Inducing the Autophagy on Spinal Cord Injury in the Rat Model.
Cardiovascular Diseases
On- and Off-Target Pharmacology of Torcetrapib: Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors.
Cardiovascular Diseases
Optimal therapy of low levels of high density lipoprotein-cholesterol.
Cardiovascular Diseases
Optimizing cardiovascular outcomes in diabetes mellitus.
Cardiovascular Diseases
Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Cardiovascular Diseases
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Cardiovascular Diseases
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Cardiovascular Diseases
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
Cardiovascular Diseases
Pleiotropic effects of HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Cardiovascular Diseases
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Cardiovascular Diseases
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Cardiovascular Diseases
Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Cardiovascular Diseases
Potential role of statin therapy in heart failure, atrial fibrillation and aortic stenosis.
Cardiovascular Diseases
Potential therapeutic role of statins in neurological disorders.
Cardiovascular Diseases
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Cardiovascular Diseases
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Cardiovascular Diseases
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Cardiovascular Diseases
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Cardiovascular Diseases
Regulation of lipid metabolism in chicken liver by dietary cereals.
Cardiovascular Diseases
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cardiovascular Diseases
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Cardiovascular Diseases
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Cardiovascular Diseases
Role of C-reactive protein in cardiovascular disease.
Cardiovascular Diseases
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Cardiovascular Diseases
Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
Cardiovascular Diseases
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Cardiovascular Diseases
Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice.
Cardiovascular Diseases
Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells.
Cardiovascular Diseases
Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes.
Cardiovascular Diseases
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Cardiovascular Diseases
Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling.
Cardiovascular Diseases
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Cardiovascular Diseases
Statin mediated protection of the ischemic myocardium.
Cardiovascular Diseases
Statin therapy and myocardial no-reflow.
Cardiovascular Diseases
Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Cardiovascular Diseases
Statin use and breast cancer: do we need more evidence and what should this be?
Cardiovascular Diseases
Statin Use in Prostate Cancer: An Update.
Cardiovascular Diseases
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Cardiovascular Diseases
Statins and ALS: the possible role of impaired LXR signaling.
Cardiovascular Diseases
Statins and cardioprotection - More than just lipid lowering?
Cardiovascular Diseases
Statins and the liver.
Cardiovascular Diseases
Statins and the Liver.
Cardiovascular Diseases
Statins and venous thromboembolism: do they represent a viable therapeutic agent?
Cardiovascular Diseases
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.
Cardiovascular Diseases
Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
Cardiovascular Diseases
Statins impair glucose uptake in tumor cells.
Cardiovascular Diseases
Statins in acute coronary syndrome: very early initiation and benefits.
Cardiovascular Diseases
Statins in chronic kidney disease and kidney transplantation.
Cardiovascular Diseases
Statins in COPD: A Systematic Review.
Cardiovascular Diseases
Statins in the 21st century: end of the simple story?
Cardiovascular Diseases
Statins in the spectrum of neurologic disease.
Cardiovascular Diseases
Statins potently reduce the cytokine-mediated IL-6 release in SMC / MNC cocultures.
Cardiovascular Diseases
Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation.
Cardiovascular Diseases
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Cardiovascular Diseases
Statins, cardiovascular disease, and drug safety.
Cardiovascular Diseases
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Cardiovascular Diseases
The beneficial effects of statins in autoimmune disease therapy.
Cardiovascular Diseases
The effects of lipid-lowering agents on acute renal allograft rejection.
Cardiovascular Diseases
The Effects of Statin Therapy on the Human Airway.
Cardiovascular Diseases
The effects of statins on endothelium, inflammation and cardioprotection.
Cardiovascular Diseases
The Impact of Exercise on Statin-Associated Skeletal Muscle Myopathy.
Cardiovascular Diseases
The role of HMGCR alternative splicing in statin efficacy.
Cardiovascular Diseases
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Cardiovascular Diseases
The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
Cardiovascular Diseases
The use of fluvastatin in cardiovascular risk management.
Cardiovascular Diseases
Therapeutic value of statins for vascular remodeling.
Cardiovascular Diseases
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Cardiovascular Diseases
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Cardiovascular Diseases
Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Cardiovascular Diseases
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Cardiovascular Diseases
[HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]
Cardiovascular Diseases
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
Cardiovascular Diseases
[Inhibitors of HMG CoA reductase: new modes of action, new indications?]
Cardiovascular Diseases
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
Cardiovascular Diseases
[Regulatory Mechanisms and Practical Management in Vascular Calcification. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment.]
Cardiovascular Diseases
[Statins and asthma].
Carotid Artery Diseases
Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors.
Carotid Artery Diseases
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Carotid Artery Diseases
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
Carotid Stenosis
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Carotid Stenosis
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Cataract
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Cataract
Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats.
Cataract
On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Cataract
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Central Nervous System Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
Central Nervous System Neoplasms
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Cerebellar Ataxia
Statin-associated cerebellar ataxia. A Brazilian case series.
Cerebral Hemorrhage
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Cerebral Hemorrhage
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Cerebral Hemorrhage
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
Cerebral Hemorrhage
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
Cerebral Infarction
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Cerebral Infarction
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
Cerebrovascular Disorders
Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
Cerebrovascular Disorders
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Cerebrovascular Disorders
Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Cerebrovascular Disorders
Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats.
Cerebrovascular Disorders
Simvastatin treatment in surgically induced brain injury in rats.
Cerebrovascular Disorders
Statins and neuroprotection: a prescription to move the field forward.
Cerebrovascular Disorders
Statins therapy: a review on conventional and novel formulation approaches.
Cerebrovascular Disorders
The acute (cerebro)vascular effects of statins.
Cholangiocarcinoma
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Cholelithiasis
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Cholelithiasis
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Cholestasis
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Cholestasis
Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Cholesterol Ester Storage Disease
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Cholesterol Ester Storage Disease
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Cholesterol Ester Storage Disease
Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease.
Choriocarcinoma
Regulation by plasma lipoproteins of progesterone biosynthesis and 3-hydroxy-3-methyl glutaryl coenzyme a reductase activity in cultured human choriocarcinoma cells.
Choroidal Neovascularization
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Colitis
Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
Colitis
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Colitis, Ulcerative
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Colonic Neoplasms
Cholesterol metabolism and colon cancer.
Colonic Neoplasms
Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line.
Colonic Neoplasms
Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line.
Colonic Neoplasms
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Colonic Neoplasms
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Colonic Neoplasms
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Colonic Neoplasms
HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Colonic Neoplasms
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Colonic Neoplasms
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Colonic Neoplasms
Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer.
Colonic Neoplasms
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Colonic Neoplasms
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Colorectal Neoplasms
Cardiovascular medication use and risk for colorectal cancer.
Colorectal Neoplasms
Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention.
Colorectal Neoplasms
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Colorectal Neoplasms
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor.
Colorectal Neoplasms
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Colorectal Neoplasms
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Colorectal Neoplasms
Gamma-tocopherol enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29).
Colorectal Neoplasms
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Colorectal Neoplasms
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Colorectal Neoplasms
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Colorectal Neoplasms
Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.
Colorectal Neoplasms
Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis.
Colorectal Neoplasms
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study.
Colorectal Neoplasms
Statins and the colorectum: hope for chemoprevention?
Colorectal Neoplasms
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Colorectal Neoplasms
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Colorectal Neoplasms
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
Communicable Diseases
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Confusion
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Connective Tissue Diseases
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.
Connective Tissue Diseases
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
Connective Tissue Diseases
[Necrotizing myopathies: From genetic to acquired forms.]
Coronary Artery Disease
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
Coronary Artery Disease
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Coronary Artery Disease
Addressing the spectrum of hypercholesterolemia.
Coronary Artery Disease
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Coronary Artery Disease
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Coronary Artery Disease
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Coronary Artery Disease
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Coronary Artery Disease
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
Coronary Artery Disease
Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese.
Coronary Artery Disease
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Coronary Artery Disease
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Coronary Artery Disease
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Coronary Artery Disease
Do statins prevent heart failure in patients after myocardial infarction?
Coronary Artery Disease
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Coronary Artery Disease
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Coronary Artery Disease
Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data from a Prospective, Randomized, Double-Blind Study.
Coronary Artery Disease
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Coronary Artery Disease
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Coronary Artery Disease
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Coronary Artery Disease
Effect of pravastatin on plasma sterols and oxysterols in men.
Coronary Artery Disease
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
Coronary Artery Disease
Effect of statins on atherogenic serum amyloid A and ?1-antitrypsin low-density lipoprotein complexes.
Coronary Artery Disease
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Coronary Artery Disease
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Coronary Artery Disease
Effects of lovastatin and pravastatin on cognitive function in military aircrew.
Coronary Artery Disease
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Coronary Artery Disease
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Coronary Artery Disease
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Coronary Artery Disease
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Coronary Artery Disease
Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Coronary Artery Disease
Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation.
Coronary Artery Disease
Evaluation of the promoter polymorphism -911C>A in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase gene with coronary artery disease risk and cholesterol levels in a population from Western India.
Coronary Artery Disease
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
Coronary Artery Disease
Ezetimibe and Vascular Inflammation.
Coronary Artery Disease
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
Coronary Artery Disease
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Coronary Artery Disease
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
Coronary Artery Disease
HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
Coronary Artery Disease
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Coronary Artery Disease
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Coronary Artery Disease
HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms?
Coronary Artery Disease
HMG-CoA reductase inhibitors: a look back and a look ahead.
Coronary Artery Disease
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Coronary Artery Disease
IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Coronary Artery Disease
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Coronary Artery Disease
Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy.
Coronary Artery Disease
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Coronary Artery Disease
Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Coronary Artery Disease
Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic.
Coronary Artery Disease
Low-density lipoprotein apheresis therapy during pregnancy.
Coronary Artery Disease
Medical management of coronary artery disease revisited: the endothelial factor.
Coronary Artery Disease
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Coronary Artery Disease
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Coronary Artery Disease
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Coronary Artery Disease
Noncholesterol-lowering effects of statins.
Coronary Artery Disease
Pathophysiology and treatment of lipid perturbation after cardiac transplantation.
Coronary Artery Disease
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Coronary Artery Disease
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.
Coronary Artery Disease
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Coronary Artery Disease
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Coronary Artery Disease
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Coronary Artery Disease
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Coronary Artery Disease
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Coronary Artery Disease
Provider adherence to clinical guidelines related to lipid-lowering medications.
Coronary Artery Disease
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Coronary Artery Disease
Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention.
Coronary Artery Disease
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Coronary Artery Disease
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Coronary Artery Disease
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
Coronary Artery Disease
Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Coronary Artery Disease
Role of circulating lipid abnormalities in chronic renal allograft rejection.
Coronary Artery Disease
Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.
Coronary Artery Disease
Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart.
Coronary Artery Disease
Statins in stroke: prevention, protection and recovery.
Coronary Artery Disease
Statins, cardiovascular disease, and drug safety.
Coronary Artery Disease
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
Coronary Artery Disease
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Coronary Artery Disease
The effect of statin therapy on allergic patients with asthma.
Coronary Artery Disease
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
Coronary Artery Disease
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
Coronary Artery Disease
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
Coronary Artery Disease
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
Coronary Artery Disease
The role of statins in heart failure.
Coronary Artery Disease
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Coronary Artery Disease
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Coronary Artery Disease
Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
Coronary Artery Disease
[Cardiologists and limitations of statins reimbursement]
Coronary Artery Disease
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits]
Coronary Artery Disease
[The impact HMG-CoA reductase inhibitors in the modification of the natural history of coronary artery disease]
Coronary Artery Disease
[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease]
Coronary Disease
8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.
Coronary Disease
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
Coronary Disease
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Coronary Disease
Aggressive statin therapy for acute coronary syndromes.
Coronary Disease
Antioxidative effects of statins.
Coronary Disease
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Coronary Disease
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Coronary Disease
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Coronary Disease
Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
Coronary Disease
CHD: a major burden in type 2 diabetes.
Coronary Disease
Clinical pharmacokinetics of fluvastatin.
Coronary Disease
Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Coronary Disease
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Coronary Disease
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Coronary Disease
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Coronary Disease
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Coronary Disease
Cost-effectiveness of statins.
Coronary Disease
Debate: at what level of coronary heart disease risk should a statin be prescribed?
Coronary Disease
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Coronary Disease
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Coronary Disease
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Coronary Disease
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Coronary Disease
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Coronary Disease
Effective use of statins to prevent coronary heart disease.
Coronary Disease
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Coronary Disease
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Coronary Disease
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Coronary Disease
Evaluation and management of lipid disorders.
Coronary Disease
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Coronary Disease
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
Coronary Disease
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Coronary Disease
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Coronary Disease
HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease.
Coronary Disease
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Coronary Disease
Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
Coronary Disease
Intensive statin therapy in acute coronary syndromes.
Coronary Disease
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Coronary Disease
Lipid and non-lipid effects of statins.
Coronary Disease
Lipid-lowering for prevention of coronary heart disease: what policy now?
Coronary Disease
Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Coronary Disease
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Coronary Disease
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Coronary Disease
Optimal medical management of peripheral arterial disease.
Coronary Disease
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Coronary Disease
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
Coronary Disease
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Coronary Disease
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Coronary Disease
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
Coronary Disease
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Coronary Disease
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Coronary Disease
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Coronary Disease
Reduction of serum LDL-C levels: a relationship to clinical benefits.
Coronary Disease
Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Coronary Disease
Results of recent large cholesterol-lowering trials and implications for clinical management.
Coronary Disease
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Coronary Disease
Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
Coronary Disease
Statin therapy in the elderly: does it make good clinical and economic sense?
Coronary Disease
Statin treatment and progression of atherosclerotic plaque burden.
Coronary Disease
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Coronary Disease
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Coronary Disease
Statins for primary prevention: at what coronary risk is safety assured?
Coronary Disease
Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Coronary Disease
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Coronary Disease
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Coronary Disease
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
Coronary Disease
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Coronary Disease
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
Coronary Disease
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
Coronary Disease
The management of cholesterol in coronary heart disease risk reduction.
Coronary Disease
What do the statins tell us?
Coronary Disease
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Coronary Disease
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
Coronary Disease
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
Coronary Disease
[HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality]
Coronary Disease
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
Coronary Disease
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease]
Coronary Disease
[The role of cholesterol-lowering drugs in prevention of coronary heart disease]
Coronary Restenosis
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis.
Coronary Stenosis
Positron emission tomography and the changing paradigm in coronary artery disease.
Cough
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Cystic Fibrosis
Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C.
Death, Sudden, Cardiac
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Dehydration
Effect of prolonged water stress on essential oil content, compositions and gene expression patterns of mono- and sesquiterpene synthesis in two oregano (Origanum vulgare L.) subspecies.
Dehydration
Role of phytosterols in drought stress tolerance in rice.
Delirium
Statins and delirium: is there a role?
Dementia
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Dementia
Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.
Dementia
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Dementia
Non-atheroprotective effects of statins: a systematic review.
Dementia
Risk factors for dementia in patients over 65 with diabetes.
Dementia
Risk factors for dementia with type 2 diabetes mellitus among elderly people in China.
Dementia
The Effect of HMG: CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study.
Dementia
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
Dementia, Vascular
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Demyelinating Diseases
Tellurium causes dose-dependent coordinate down-regulation of myelin gene expression.
Dengue
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Dermatitis, Phototoxic
Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts.
Dermatitis, Phototoxic
The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct.
Dermatomyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Dermatomyositis
[Pravastatin-induced dermatomyositis]
Diabetes Mellitus
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Diabetes Mellitus
Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis.
Diabetes Mellitus
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Diabetes Mellitus
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Diabetes Mellitus
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Diabetes Mellitus
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Diabetes Mellitus
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Diabetes Mellitus
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Diabetes Mellitus
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Diabetes Mellitus
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Diabetes Mellitus
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Diabetes Mellitus
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Diabetes Mellitus
Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
Diabetes Mellitus
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Diabetes Mellitus
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
Diabetes Mellitus
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Diabetes Mellitus
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Diabetes Mellitus
Lipids and stroke: the opportunity of lipid-lowering treatment.
Diabetes Mellitus
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Diabetes Mellitus
Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).
Diabetes Mellitus
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
Diabetes Mellitus
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.
Diabetes Mellitus
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Diabetes Mellitus
Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.
Diabetes Mellitus
Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
Diabetes Mellitus
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Diabetes Mellitus
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Diabetes Mellitus
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Diabetes Mellitus
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Diabetes Mellitus
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Diabetes Mellitus
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Diabetes Mellitus, Experimental
Influence of streptozotocin diabetes on intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the rat.
Diabetes Mellitus, Type 1
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Diabetes Mellitus, Type 1
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase.
Diabetes Mellitus, Type 2
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Diabetes Mellitus, Type 2
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Diabetes Mellitus, Type 2
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Diabetes Mellitus, Type 2
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Diabetes Mellitus, Type 2
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Diabetes Mellitus, Type 2
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Diabetes Mellitus, Type 2
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Diabetes Mellitus, Type 2
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Diabetes Mellitus, Type 2
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Diabetes Mellitus, Type 2
Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
Diabetes Mellitus, Type 2
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Diabetes Mellitus, Type 2
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Diabetes Mellitus, Type 2
Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Diabetes Mellitus, Type 2
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Diabetes Mellitus, Type 2
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Diabetes Mellitus, Type 2
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Diabetes Mellitus, Type 2
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Lipids and stroke: the opportunity of lipid-lowering treatment.
Diabetes Mellitus, Type 2
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Management of dyslipidemia in NIDDM.
Diabetes Mellitus, Type 2
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Diabetes Mellitus, Type 2
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Diabetes Mellitus, Type 2
Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.
Diabetes Mellitus, Type 2
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Diabetes Mellitus, Type 2
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Diabetes Mellitus, Type 2
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetes Mellitus, Type 2
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Diabetes Mellitus, Type 2
Should the insulin resistance syndrome be treated in the elderly?
Diabetes Mellitus, Type 2
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
Diabetes Mellitus, Type 2
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Diabetes Mellitus, Type 2
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Diabetes Mellitus, Type 2
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
Diabetes Mellitus, Type 2
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Diabetes Mellitus, Type 2
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Diabetes Mellitus, Type 2
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Diabetes Mellitus, Type 2
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Diabetic Angiopathies
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Diabetic Foot
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Diabetic Nephropathies
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Diabetic Nephropathies
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Diabetic Nephropathies
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic Nephropathies
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Diabetic Nephropathies
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Diabetic Nephropathies
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.
Diabetic Nephropathies
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Diabetic Nephropathies
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.
Diabetic Nephropathies
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.
Diabetic Nephropathies
Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.
Diabetic Nephropathies
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Diabetic Neuropathies
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Diabetic Retinopathy
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic Retinopathy
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Diabetic Retinopathy
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Diabetic Retinopathy
Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.
Drug Eruptions
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Drug Eruptions
Pravastatin-induced lichenoid drug eruption.
Drug-Related Side Effects and Adverse Reactions
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.
Drug-Related Side Effects and Adverse Reactions
HMG-CoA reductase inhibitors and myotoxicity.
Drug-Related Side Effects and Adverse Reactions
HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.
Drug-Related Side Effects and Adverse Reactions
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Drug-Related Side Effects and Adverse Reactions
Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.
Drug-Related Side Effects and Adverse Reactions
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Dyskinesias
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Dyslipidemias
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Dyslipidemias
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Dyslipidemias
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Dyslipidemias
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
Dyslipidemias
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Dyslipidemias
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Dyslipidemias
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Dyslipidemias
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
Dyslipidemias
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Dyslipidemias
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Dyslipidemias
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Dyslipidemias
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Dyslipidemias
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Dyslipidemias
Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Dyslipidemias
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Dyslipidemias
Diabetes and metabolic syndrome (MS).
Dyslipidemias
Dyslipidemia and coronary artery disease.
Dyslipidemias
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Dyslipidemias
Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
Dyslipidemias
Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients.
Dyslipidemias
Dyslipidemias in diabetic patients. Is standard cholesterol treatment appropriate?
Dyslipidemias
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Dyslipidemias
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Dyslipidemias
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Dyslipidemias
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Dyslipidemias
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Dyslipidemias
Effects of prickly pear dried leaves, artichoke leaves, turmeric and garlic extracts, and their combinations on preventing dyslipidemia in rats.
Dyslipidemias
Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
Dyslipidemias
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Dyslipidemias
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
Dyslipidemias
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Dyslipidemias
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Dyslipidemias
Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Dyslipidemias
Implications of recent statin trials for primary care practice.
Dyslipidemias
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Dyslipidemias
Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.
Dyslipidemias
Interactions between grapefruit juice and cardiovascular drugs.
Dyslipidemias
Investigations of statins in heart failure: inflammatory biomarkers and hormones.
Dyslipidemias
Lipid-lowering medications for children and adolescents.
Dyslipidemias
Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.
Dyslipidemias
Management of diabetic dyslipidemia: need for reappraisal of the goals.
Dyslipidemias
Management of dyslipidemia in adults.
Dyslipidemias
Managing dyslipidemia in chronic kidney disease.
Dyslipidemias
Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Dyslipidemias
Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
Dyslipidemias
Myopathy associated with atorvastatin-ezetimibe combination therapy.
Dyslipidemias
Optimizing cardiovascular outcomes in diabetes mellitus.
Dyslipidemias
Pathogenesis and management of diabetic dyslipidemia.
Dyslipidemias
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Dyslipidemias
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Dyslipidemias
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Dyslipidemias
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Dyslipidemias
Pitavastatin: a new HMG-CoA reductase inhibitor.
Dyslipidemias
Potential Correlation between Statins and Pulp Chamber Calcification.
Dyslipidemias
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Dyslipidemias
Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
Dyslipidemias
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Dyslipidemias
Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Dyslipidemias
Rosuvastatin for the treatment of hypercholesterolemia.
Dyslipidemias
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Dyslipidemias
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Dyslipidemias
Rosuvastatin: a review of its effect on atherosclerosis.
Dyslipidemias
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Dyslipidemias
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Dyslipidemias
Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.
Dyslipidemias
Simvastatin evokes an unpredicted inhibition of ?-adrenoceptor-mediated vasodilatation in porcine coronary artery.
Dyslipidemias
Statin use and cognitive changes in elderly patients with dementia.
Dyslipidemias
Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Dyslipidemias
Statins in oncological research: from experimental studies to clinical practice.
Dyslipidemias
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
Dyslipidemias
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
Dyslipidemias
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
Dyslipidemias
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
Dyslipidemias
The potential behavioral and economic impacts of widespread HMG-CoA reductase inhibitor (statin) use.
Dyslipidemias
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Dyslipidemias
Therapeutic value of statins for vascular remodeling.
Dyslipidemias
Treatment of Alport syndrome: beyond animal models.
Dyslipidemias
Treatment of diabetic dyslipidemia.
Dyslipidemias
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Dyslipidemias
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.
Dyslipidemias
Vascular disease and lipids in diabetes.
Dyslipidemias
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Dyslipidemias
[Diabetes and multimetabolic syndrome]
Dyslipidemias
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
Dyslipidemias
[Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet]
Dyslipidemias
[Lipid-lowering therapy in the prevention of coronary heart disease]
Dyslipidemias
[Statin pharmacokinetics]
Dyslipidemias
[Statins in the management of acute coronary syndrome]
Dyslipidemias
[The treatment of refractory hyperlipoproteinemias]
Dyslipidemias
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance]
Encephalomyelitis
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Encephalomyelitis
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Encephalomyelitis
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Encephalomyelitis, Autoimmune, Experimental
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Encephalomyelitis, Autoimmune, Experimental
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Endometrial Neoplasms
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Endometriosis
Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Eosinophilia
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia.
Ependymoma
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Epilepsy
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Epilepsy
The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.
Epilepsy
Use of antiepileptic drugs and lipid-lowering agents in the United States.
Erectile Dysfunction
Comment: HMG-CoA reductase inhibitor-induced impotence.
Erectile Dysfunction
HMG CoA Reductase Inhibitors and Impotence: Two Case Series from the Spanish and French Drug Monitoring Systems.
Erectile Dysfunction
HMG-CoA reductase inhibitor-induced impotence.
Esophageal Squamous Cell Carcinoma
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Essential Hypertension
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Essential Hypertension
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Essential Hypertension
Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension.
Essential Hypertension
Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.
Exanthema
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Exanthema
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
Eye Diseases
Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases.
Fatigue Syndrome, Chronic
Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis.
Fatty Liver
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Fatty Liver
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Fatty Liver
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Fatty Liver
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Fatty Liver
Oxysterols and alcoholic liver disease.
Fatty Liver
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Fatty Liver
Rice bran enzymatic extract reduces atherosclerotic plaque development and steatosis in high-fat fed ApoE-/- mice.
Fatty Liver
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
Fatty Liver
Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid.
Fatty Liver, Alcoholic
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Fibrosarcoma
Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells.
Fibrosarcoma
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Fragile X Syndrome
The genetics of mental retardation.
Gallstones
3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme.
Gallstones
Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
Gallstones
Antilithiasic effect of beta-cyclodextrin in LPN hamster: comparison with cholestyramine.
Gallstones
Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid.
Gallstones
Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
Gallstones
Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.
Gallstones
Cholesterol synthesis inhibitors in cholesterol gallstone disease.
Gallstones
Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects.
Gallstones
Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Gallstones
Dietary cholesterol affects chenodeoxycholic acid action on biliary lipids.
Gallstones
Dissolution of cholesterol gallstones by bile acids in hamsters.
Gallstones
Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.
Gallstones
Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Gallstones
Effects of bezafibrate on hepatic cholesterol metabolism.
Gallstones
Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
Gallstones
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Gallstones
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Gallstones
Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Gallstones
Hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in hamsters on a lithogenic diet.
Gallstones
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Gallstones
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
Gallstones
Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Gallstones
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Gallstones
Hepatic cholesterol metabolism in patients with cholesterol gallstones: enhanced intracellular transport of cholesterol.
Gallstones
Hepatic cholesterol metabolism in patients with gallstones.
Gallstones
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Gallstones
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Gallstones
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Gallstones
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Gallstones
Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis.
Gallstones
Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
Gallstones
Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.
Gallstones
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Gallstones
Rowachol and ursodeoxycholic acid in hamsters with cholesterol gallstones.
Gallstones
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
Gallstones
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Gallstones
Therapeutic Reflections In Cholesterol Homeostasis And Gallstone Disease. A Review.
Gallstones
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Gallstones
Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Gallstones
[Experimental study on hepatic HMG-CoA reductase activity in relation to the formation and dissolution of cholesterol gallstones (author's transl)]
Gastroesophageal Reflux
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Glaucoma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Glaucoma, Open-Angle
The Relationship Between Statin Use and Open-Angle Glaucoma.
Glioblastoma
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Glioblastoma
HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model.
Glioblastoma
HMGCR positively regulated the growth and migration of glioblastoma cells.
Glioblastoma
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Glioblastoma
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Glioma
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Glioma
HMG CoA reductase inhibitors, NSAIDs and risk of glioma.
Glioma
In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
Glioma
Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?
Glioma
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Glioma
Regulation of sterol synthesis and of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipoproteins in glial cells in primary culture.
Glioma
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Glomerulonephritis
Effect of simvastatin on proliferative nephritis and cell-cycle protein expression.
Glomerulonephritis
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Glomerulonephritis
Statins and progressive renal disease.
Glomerulonephritis, IGA
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Glomerulonephritis, IGA
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy.
Glomerulonephritis, IGA
Statins and progressive renal disease.
Glomerulonephritis, Membranous
Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Glucose Intolerance
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Glucose Intolerance
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Glucose Intolerance
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Glucose Intolerance
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Glucosephosphate Dehydrogenase Deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Goiter
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.
Graft vs Host Disease
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
Graft vs Host Disease
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
Graft vs Host Disease
Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Gynecomastia
Golf-inhibiting gynecomastia associated with atorvastatin therapy.
Gynecomastia
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature.
Hearing Loss
Fluvastatin protects cochleae from damage by high-level noise.
Hearing Loss
Irreversible atorvastatin-associated hearing loss.
Hearing Loss, Sensorineural
Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL).
Heart Diseases
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Heart Diseases
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Heart Diseases
Development of thyroid follicular adenoma on simvastatin therapy.
Heart Diseases
HMG-CoA reductase inhibitors in the prevention of stroke.
Heart Diseases
Impact of statins on novel risk markers.
Heart Diseases
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Heart Diseases
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Heart Diseases
[Early statin treatment in acute coronary syndrome. Is this evidence-based?]
Heart Failure
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Heart Failure
Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure.
Heart Failure
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Heart Failure
Do statins have a role in the management of diastolic dysfunction?
Heart Failure
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Heart Failure
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Heart Failure
Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II.
Heart Failure
Inflammation in chronic heart failure.
Heart Failure
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Heart Failure
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Heart Failure
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Heart Failure
Potential autonomic nervous system effects of statins in heart failure.
Heart Failure
Potential role of statins in the treatment of heart failure.
Heart Failure
Provider adherence to clinical guidelines related to lipid-lowering medications.
Heart Failure
Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
Heart Failure
Simvastatin normalizes autonomic neural control in experimental heart failure.
Heart Failure
Statin therapy for cardiac hypertrophy and heart failure.
Heart Failure
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Heart Failure
Statins and left ventricular function.
Heart Failure
Statins and the myocardium.
Heart Failure
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Heart Failure
The nutritional and metabolic support of heart failure in the intensive care unit.
Heart Failure
The role of statin therapy in the management of cardiomyopathies.
Heart Failure
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Heart Failure, Systolic
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Hemangioma, Cavernous, Central Nervous System
The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
Hematologic Neoplasms
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
Hematologic Neoplasms
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Hepatitis
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
Hepatitis
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Hepatitis
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Hepatitis
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Hepatitis
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
Hepatitis
[Acute cholestatic hepatitis after atorvastatin reintroduction.]
Hepatitis C
Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Hepatitis C
Dihydroquercetin: More than just an impurity?
Hepatitis C
Do statins reduce hepatitis C RNA titers during routine clinical use?
Hepatitis C
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Hepatitis C
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hepatitis C, Chronic
Do statins reduce hepatitis C RNA titers during routine clinical use?
Hepatitis, Autoimmune
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
Hepatoblastoma
Growth requirements and expression of LDL receptor and HMG-CoA reductase in Hep G2 hepatoblastoma cells cultured in a chemically defined medium.
Hepatoblastoma
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Hepatoblastoma
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
Hepatoblastoma
The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells.
Herpes Zoster
Differential ACTH response of immunodetectable HMG CoA reductase and cytochromes P450(17 alpha) and P450(21) in guinea pig adrenal outer zone cell types, zona glomerulosa and zona fasciculata.
Histiocytoma, Malignant Fibrous
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
HIV Infections
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
HIV Infections
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Huntington Disease
Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease.
Hyperalgesia
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Hyperalgesia
RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.
Hypercholesterolemia
'Muscle-sparing' statins: preclinical profiles and future clinical use.
Hypercholesterolemia
3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS.
Hypercholesterolemia
3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia?
Hypercholesterolemia
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
Hypercholesterolemia
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Hypercholesterolemia
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Hypercholesterolemia
A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia.
Hypercholesterolemia
A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
Hypercholesterolemia
A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway.
Hypercholesterolemia
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Hypercholesterolemia
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hypercholesterolemia
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
Hypercholesterolemia
A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
Hypercholesterolemia
A review of current clinical findings with fluvastatin.
Hypercholesterolemia
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Hypercholesterolemia
Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression.
Hypercholesterolemia
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Hypercholesterolemia
Adverse effects of long-term exposure to bisphenol A during adulthood leading to hyperglycaemia and hypercholesterolemia in mice.
Hypercholesterolemia
Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective).
HOME
login
history
all enzymes
BRENDA home
History
Enzyme Nomenclature
top
